Clinical trial · no report yet · Phase 2
NAUTIKA 1
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- NCT04302025 ↗
- Recruiting
- Genentech, Inc.
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 25 | |
| YouTube | 24 | |
| Podcasts | 15 |
The trial
ClinicalTrials.gov- Official title
- NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Alectinib; Entrectinib; Vemurafenib; Cobimetinib; Pralsetinib; Atezolizumab; SBRT; Resection; Chemotherapy; Divarasib
- Arms
- ALK Cohort (Enrolment Closed) · Experimental
- ROS 1 Cohort (Enrolment Closed) · Experimental
- NTRK Cohort (Enrolment Closed) · Experimental
- BRAF Cohort (No Participants Enrolled, Cohort Closed) · Experimental
- RET Cohort (Cohort closed) · Experimental
- PD-L1 Cohort (Enrolment Closed) · Experimental
- KRAS G12C Cohort · Experimental
- Enrollment
- 99 (estimated)
- Primary outcomes
- Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)
- Checkpoint Inhibitor (CPI) Cohort: Pathological Complete Response (pCR)
- KRAS G12C Cohort: Percentage of Participants With 3-5 Grade Adverse Events (AEs)
- KRAS G12C Cohort: Percentage of Participants Without Delays of Surgery due to Treatment-related AEs as Reported by the Investigator
- Sponsor
- Genentech, Inc.
- Start
- Nov 6, 2020
- Primary completion
- Nov 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04302025 · updated Oct 13, 2026